One four-residue motif, His-Phe-Arg-Trp, can drive pigmentation, appetite, inflammation or sexual behaviour. Which of those it drives depends only on which melanocortin receptor it reaches first. That makes the system rewarding to study and easy to misread. Melanotan II and PT-141 are the two analogues most often used in that work. They differ by exactly one chemical bond: a hydrolysed amide that reshapes the entire pharmacological profile.
One peptide family, five receptors
All melanocortins derive from pro-opiomelanocortin (POMC). Prohormone convertases process that precursor into adrenocorticotropic hormone (ACTH), the melanocyte-stimulating hormones (α-, β- and γ-MSH) and β-endorphin. α-MSH is a thirteen-residue peptide. Decades of structure-activity work narrowed its active core to the His-Phe-Arg-Trp sequence at positions 6-9. Nearly every synthetic analogue in the literature is built around that motif.
Five class A G-protein-coupled receptors respond to it, all canonically coupled to Gαs and cyclic AMP accumulation:
- MC1R: melanocytes, plus keratinocytes and immune cells. The pigmentation and cutaneous anti-inflammatory receptor.
- MC2R: adrenal cortex. The ACTH receptor, and the only subtype that does not respond to α-MSH.
- MC3R: hypothalamus and periphery. Implicated in energy partitioning and, in rodent work, in the timing of pubertal development.
- MC4R: predominantly central nervous system. The best-characterised regulator of energy homeostasis, and central to erectile and proceptive behaviour in rodent models.
- MC5R: exocrine and sebaceous tissue, with reported roles in lipid secretion and lymphocyte function.
The therapeutic relevance of this family is no longer speculative. Afamelanotide, a linear α-MSH analogue, is authorised in the EU for erythropoietic protoporphyria. Setmelanotide is approved for rare genetic obesity caused by POMC, LEPR or Bardet-Biedl pathway defects. Both were validated through the same receptor assays used in exploratory laboratory work.
Melanotan II: a conformationally constrained, non-selective agonist
Melanotan II is a cyclic lactam heptapeptide. A bridge between an aspartate and a lysine side chain locks the His-D-Phe-Arg-Trp message sequence into a β-turn. That turn resembles the receptor-bound conformation of native α-MSH.
Two further substitutions matter for assay work. Replacing methionine with norleucine removes an oxidation-prone side chain. The D-phenylalanine at the position corresponding to Phe7 blocks chymotrypsin-like cleavage. The result is a compound far more potent than α-MSH in cAMP assays. It is also considerably more resistant to proteolysis in serum-containing media.
What cyclisation does not deliver is selectivity. Published binding and functional data place Melanotan II as a broad agonist at MC1R, MC3R, MC4R and MC5R. The separation between subtypes is only modest. In a cell line expressing a single recombinant receptor that is unproblematic.
In any preparation containing multiple subtypes (primary skin cells, hypothalamic slices, whole-animal work), every observed effect is a composite. Attributing it to one receptor requires either subtype-selective antagonists or genetic knockouts. Research-grade Melanotan II is therefore best treated as a pan-melanocortin probe rather than a pigmentation-specific tool.
Eumelanin, pheomelanin and photoprotection models
MC1R agonism in melanocytes raises cAMP, activates protein kinase A and phosphorylates CREB. That upregulates the transcription factor MITF. MITF in turn drives tyrosinase, TYRP1 and dopachrome tautomerase. They are the enzymatic machinery that shifts synthesis from pheomelanin towards eumelanin.
The distinction is functional, not cosmetic. Eumelanin is a broadband absorber and radical scavenger. Pheomelanin absorbs poorly. Under UVA exposure in cell-free and cellular systems, it can act as a source of reactive oxygen species. Loss-of-function MC1R variants associated with the red-hair phenotype leave melanocytes locked in a pheomelanin-dominant state. That is why those variants recur throughout the photobiology literature as a risk marker independent of UV exposure.
Standard in-vitro models reflect this pathway directly:
- melanin content and tyrosinase activity in B16 murine melanoma cells or normal human melanocytes
- MITF and tyrosinase transcript levels by qPCR
- UV-challenge assays reading out cyclobutane pyrimidine dimer formation or comet-assay DNA damage
Reported findings are genuinely mixed on whether MC1R signalling enhances nucleotide excision repair capacity beyond the optical shielding provided by additional eumelanin. The dermatological literature also documents naevus changes and isolated melanoma case reports in people who obtained unregulated melanotropic material. Both strands belong in any honest framing of this target.
PT-141: one bond of difference
PT-141, or bremelanotide, is the des-amide metabolite of Melanotan II. Hydrolysis of the C-terminal amide leaves a free carboxylic acid. That single change collapses melanogenic potency relative to central activity, while preserving strong agonism at MC4R and MC3R. The added negative charge alters both the receptor contact surface and the physicochemical profile of the molecule. That is the reason the two compounds are pharmacologically distinct rather than interchangeable.
Its development history is instructive. The compound was originally advanced as an intranasal formulation. That programme was halted after trial data showed transient increases in blood pressure. A reformulated subcutaneous version was later evaluated in two phase 3 trials in premenopausal women with hypoactive sexual desire disorder. It gained US approval in 2019. That makes PT-141 one of very few melanocortin analogues to complete late-stage clinical development.
Mechanistic work in rodents locates the relevant activity centrally, in MC4R-expressing populations of the paraventricular nucleus and medial preoptic area, rather than in peripheral vascular tissue. Approval in one indication does not change the regulatory position of laboratory material. PT-141 supplied as a research chemical remains research-use-only, and the RUO terms apply without exception.
Why selectivity dictates assay design
The practical consequence of the Melanotan II / PT-141 divergence is that the two compounds answer different questions. A cAMP dose-response series across HEK293 lines, each expressing a single human melanocortin receptor, will separate them cleanly. That is the standard approach in published pharmacology. Running that panel before any phenotypic assay is what makes the phenotypic data interpretable.
Radioligand competition against NDP-α-MSH gives orthogonal affinity data. β-arrestin recruitment assays are increasingly used, because melanocortin receptors show measurable signalling bias. cAMP EC50 alone can be a poor predictor of outcomes in intact tissue.
Two further variables deserve attention. MC4R trafficking and signalling are modulated by melanocortin receptor accessory protein 2 (MRAP2). Heterologous systems lacking MRAP2 may therefore not reproduce hypothalamic behaviour. And the endogenous antagonists agouti-related peptide and agouti signalling protein act as inverse agonists at MC4R and MC1R respectively. That means constitutive receptor activity is part of the baseline. It should be controlled for rather than assumed away.
Handling considerations
Both peptides are cyclic and comparatively robust, but robustness against proteases is not stability in a freezer. Lyophilised material should be:
- equilibrated to room temperature before opening, to avoid condensation
- reconstituted in an appropriate sterile diluent such as bacteriostatic water for stock preparation
- aliquoted
- kept away from repeated freeze-thaw cycles
Adsorption to polypropylene is a real source of apparent potency loss at low nanomolar working concentrations. Low-binding tubes and a carrier protein such as 0.1% BSA in serum-free assay medium mitigate it. PT-141’s free carboxylate makes its solubility and net charge more pH-sensitive than the amidated parent. Buffer composition is therefore worth recording alongside results. The full protocol is covered in our reconstitution and storage guide.
The research-versus-hype gap
Melanocortin analogues attract more unsupported claims than almost any other peptide class. The gap between the marketing and the literature is wide. What the published record actually supports is narrow and specific:
- MC1R agonism reliably shifts melanogenesis towards eumelanin in cell and rodent models
- MC4R agonism has demonstrable central effects on feeding and sexual behaviour in animals, one of which survived phase 3 evaluation
- non-selective agonism produces off-target activity across four receptors that is frequently mistaken for a mechanism
Nausea and flushing were the most commonly recorded adverse events in the clinical programme, consistent with broad melanocortin engagement rather than incidental. Design experiments around what the data show, not around what the compounds are reputed to do. That is the whole difference between a usable result and a wasted plate.
All products are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use.